Polycystic ovary syndrome: ovarian pathophysiology and consequences after the menopause
Polycystic ovary syndrome Ovarian pathophysiology and consequences after the menopause Johanna Schmidt Institute of Clinical Sciences at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 2011 The Polycystic Ovary Syndrome (PCOS) is an endocrine disorder affecting ~10% of women. It is characterized by oligo/anovulation, hyperandrogenism, and polycystic ovaries. PCOS is associated with acne, hirsutism, infertility, abdominal obesity, type 2 diabetes, hypertension and dyslipidemia, with the latter four being cardiovascular disease (CVD) risk factors. The aims of the thesis were to study PCOS regarding ovarian pathophysiology and postmenopausal development concerning anthropometry, reproductive hormones, bone mineral density (BMD), fractures, CVD risk factors and events and mortality. Ovarian (stroma and granulosa cells) expression in selected genes of PCOS/controls was analyzed by quantitative PCR, with special emphasis on inflammation. In the central stroma of PCOS ovaries, genes of five inflammation-related factors, one inflammation-related transcription factor and one growth factor were under-expressed. One growth factor and one coagulation factor were over-expressed. In the granulosa cells of the PCOS women, all of the differentially expressed genes were over-expressed (five inflammation-related, two coagulation-related, two growth factors, one permeability-related and one growth-arrest-related). Thirty-five PCOS women (diagnosed 1956-65) and their 120 randomly allocated age-matched controls (from the WHO MONICA study, Gothenburg), were examined in 1987 regarding anthropometry, reproductive hormones, CVD risk factors, lifestyle factors, medication and medical history (via questionnaire) and for the present thesis re-examined in 2008 (mean age 70.3 years) with the same variables. BMD was assessed by single photon absorptiometry in 1992 and by dual energy x-ray absorptiometry at follow-up in 2008. The National Board of Health and Welfare Registry and the Hospital Registry provided information on morbidity and mortality. The PCOS women still had higher free androgen index (FAI), but lower FSH than controls. Hirsutism, hypertension and hypertriglyceridemia were more common, but climacteric symptoms and hypothyroidism were less prevalent among the PCOS women. The higher waist/hip ratio among the PCOS women in 1987 could not be detected at follow-up, possibly due to an increase in hip circumference in the PCOS women and to an increase in weight among the controls. BMD, fractures, diabetes, CVD events, total mortality and cancer incidence were similar in the PCOS women and controls at follow-up. In conclusion, the ovaries of the PCOS women showed differences in the expression of key proteins, with implications for PCOS-specific arrested folliculogenesis and OHSS risk. Late postmenopausal PCOS women were still hyperandrogenic and hirsute with persistent hypertension and hypertriglyceridemia. However, the incidence of fractures, diabetes, cancer, CVD morbidity and total mortality was similar to that of the general population. Differences in body composition had disappeared in the PCOS women compared with the controls during 21 years of follow-up.
Parts of work
I.Differential expression of inflammation-related genes in the ovarian stroma and granulosa cells of PCOS women. Submitted.II. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): A 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrinol Metab. 2011 Jul;96(7):2178-85. Epub 2011 Apr 20. ::PMID::21508129III. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: A 21-year follow-up study. J Clin Endocrinol Metab. 2011 Sep 28. [Epub ahead of print] ::PMID::21956415IV. Body composition, bone mineral density and fractures in late postmenopausal PCOS women- A long-term follow-up study. Submitted.
Doctor of Philosophy (Medicine)
University of Gothenburg. Sahlgrenska Academy
Institute of Clincial Sciences. Department of Obstetrics and Gynecology
Torsdagen den 8 december, 2011, kl. 13.00, Föreläsningssal Stammen, Kvinnokliniken, Blå stråket 6, Sahlgrenska, Sahlgrenska Universitetssjukhuset, 413 45 Göteborg
Date of defence
bone mineral density
polycystic ovary syndrome